Nanjing Hanxin Pharmaceutical Technology Co., Ltd

About Us Founded on July 6, 2021, through the restructuring of Amphastar Pharmaceuticals, Inc. (USA) China R&D Center, Nanjing Hanxin Pharmaceuticals Co., Ltd. has a registered capital of CNY 183 million. Leveraging advanced technology platforms and strong R&D capabilities, Hanxin has emerged as a global pharmaceutical Company- engaged in the research, manufacture, and sales of peptides, proteins, and polysaccharides (APIs and finished dosage forms).